Clinicogenetic characteristics of the patients with MF, presented as n (%) unless otherwise specified
| Variables . | MF, all, N = 1079 . | Prefibrotic MF, n = 29 . | PMF, n = 969 . | SMF, n = 108 . | Post-PV MF, n = 40 . | Post-ET MF, n = 65 . |
|---|---|---|---|---|---|---|
| Laboratory characteristics | ||||||
| Hb, median (Q1-Q3), g/dL | 11.6 (10.1-13.2) | 13.2 (11.5-15.0) | 11.8 (10.1-13.3) | 10.7 (9.8-11.8) | 10.7 (9.65-11.9) | 10.7 (9.9-11.8) |
| WBC count, median (Q1-Q3), × 109/L | 9.4 (6.4-14.4) | 12.4 (8.4-14.0) | 9.4 (6.5-14.3) | 8.5 (4.9-15.8) | 10.0 (5.1-19.5) | 8.2 (4.8-14.6) |
| Platelets count, median (Q1-Q3), × 109/L | 437 (215-748) | 697 (513-838) | 470 (215-763.5) | 340 (203.5-446.5) | 255 (188.5-370) | 374 (215-558) |
| Mutational status, patients diagnosed prior 31 May 2016∗ | ||||||
| JAK2 V617F | 296 (56.6) | 0 | 270 (56.7) | 26 (57.8) | 12 (100) | 13 (43.3) |
| CALR | 16 (3.1) | 0 | 14 (9.2) | 2 (4.4) | 0 | 2 (6.7) |
| MPL | 1 (0.19) | 0 | 1 (0.21) | 0 | 0 | 0 |
| Other mutation | 1 (0.19) | 0 | 1 (0.21) | 0 | 0 | 0 |
| No mutation | 201 (38.4) | 1 (100) | 185 (38.9) | 14 (31.1) | 0 | 12 (40.0) |
| Mutational status, patients diagnosed after 1 June 2016∗ | ||||||
| JAK2 V617F | 253 (53.6) | 22 (78.6) | 218 (53.7) | 13 (34.2) | 10 (71.4) | 3 (12.5) |
| JAK2 exon 12 | 2 (0.42) | 0 | 2 (0.49) | 0 | 0 | 0 |
| CALR | 90 (19.1) | 4 (14.3) | 78 (19.2) | 8 (21.2) | 0 | 8 (33.3) |
| MPL | 28 (5.9) | 2 (7.1) | 24 (5.9) | 2 (5.3) | 0 | 2 (8.3) |
| Other mutation | 31 (6.6) | 1 (3.6) | 23 (6.4) | 4 (10.5) | 2 (14.3) | 2 (8.3) |
| No mutation | 59 (12.5) | 1 (3.6) | 55 (13.5) | 3 (7.9) | 0 | 3 (12.5) |
| Symptoms at diagnosis | ||||||
| Weight loss | 115 (10.7) | 3 (10.3) | 97 (10.3) | 15 (13.9) | 13 (32.5) | 1 (1.5) |
| Pruritus | 29 (2.7) | 1 (3.4) | 25 (2.7) | 3 (2.8) | 3 (7.5) | 0 |
| Fever | 30 (2.8) | 0 | 23 (2.4) | 7 (6.5) | 5 (12.5) | 2 (3.1) |
| Night sweats | 92 (8.5) | 0 | 78 (8.3) | 14 (13.0) | 7 (17.5) | 7 (10.8) |
| Splenomegaly | 214 (19.8) | 3 (10.3) | 180 (19.2) | 31 (28.7) | 19 (47.5) | 11 (16.9) |
| IPSS category | ||||||
| Low risk | 155 (18.9) | 2 (22.2) | 141 (19.3) | 12 (15.4) | 2 (7.1) | 10 (20.4) |
| Intermediate-1 | 330 (40.3) | 5 (55.6) | 302 (41.3) | 23 (29.5) | 8 (28.6) | 15 (30.6) |
| Intermediate-2 | 197 (24.1) | 2 (22.2) | 171 (23.4) | 24 (30.8) | 10 (35.7) | 14 (28.6) |
| High risk | 136 (16.6) | 0 | 117 (16.0) | 19 (24.4) | 8 (28.6) | 10 (20.4) |
| Variables . | MF, all, N = 1079 . | Prefibrotic MF, n = 29 . | PMF, n = 969 . | SMF, n = 108 . | Post-PV MF, n = 40 . | Post-ET MF, n = 65 . |
|---|---|---|---|---|---|---|
| Laboratory characteristics | ||||||
| Hb, median (Q1-Q3), g/dL | 11.6 (10.1-13.2) | 13.2 (11.5-15.0) | 11.8 (10.1-13.3) | 10.7 (9.8-11.8) | 10.7 (9.65-11.9) | 10.7 (9.9-11.8) |
| WBC count, median (Q1-Q3), × 109/L | 9.4 (6.4-14.4) | 12.4 (8.4-14.0) | 9.4 (6.5-14.3) | 8.5 (4.9-15.8) | 10.0 (5.1-19.5) | 8.2 (4.8-14.6) |
| Platelets count, median (Q1-Q3), × 109/L | 437 (215-748) | 697 (513-838) | 470 (215-763.5) | 340 (203.5-446.5) | 255 (188.5-370) | 374 (215-558) |
| Mutational status, patients diagnosed prior 31 May 2016∗ | ||||||
| JAK2 V617F | 296 (56.6) | 0 | 270 (56.7) | 26 (57.8) | 12 (100) | 13 (43.3) |
| CALR | 16 (3.1) | 0 | 14 (9.2) | 2 (4.4) | 0 | 2 (6.7) |
| MPL | 1 (0.19) | 0 | 1 (0.21) | 0 | 0 | 0 |
| Other mutation | 1 (0.19) | 0 | 1 (0.21) | 0 | 0 | 0 |
| No mutation | 201 (38.4) | 1 (100) | 185 (38.9) | 14 (31.1) | 0 | 12 (40.0) |
| Mutational status, patients diagnosed after 1 June 2016∗ | ||||||
| JAK2 V617F | 253 (53.6) | 22 (78.6) | 218 (53.7) | 13 (34.2) | 10 (71.4) | 3 (12.5) |
| JAK2 exon 12 | 2 (0.42) | 0 | 2 (0.49) | 0 | 0 | 0 |
| CALR | 90 (19.1) | 4 (14.3) | 78 (19.2) | 8 (21.2) | 0 | 8 (33.3) |
| MPL | 28 (5.9) | 2 (7.1) | 24 (5.9) | 2 (5.3) | 0 | 2 (8.3) |
| Other mutation | 31 (6.6) | 1 (3.6) | 23 (6.4) | 4 (10.5) | 2 (14.3) | 2 (8.3) |
| No mutation | 59 (12.5) | 1 (3.6) | 55 (13.5) | 3 (7.9) | 0 | 3 (12.5) |
| Symptoms at diagnosis | ||||||
| Weight loss | 115 (10.7) | 3 (10.3) | 97 (10.3) | 15 (13.9) | 13 (32.5) | 1 (1.5) |
| Pruritus | 29 (2.7) | 1 (3.4) | 25 (2.7) | 3 (2.8) | 3 (7.5) | 0 |
| Fever | 30 (2.8) | 0 | 23 (2.4) | 7 (6.5) | 5 (12.5) | 2 (3.1) |
| Night sweats | 92 (8.5) | 0 | 78 (8.3) | 14 (13.0) | 7 (17.5) | 7 (10.8) |
| Splenomegaly | 214 (19.8) | 3 (10.3) | 180 (19.2) | 31 (28.7) | 19 (47.5) | 11 (16.9) |
| IPSS category | ||||||
| Low risk | 155 (18.9) | 2 (22.2) | 141 (19.3) | 12 (15.4) | 2 (7.1) | 10 (20.4) |
| Intermediate-1 | 330 (40.3) | 5 (55.6) | 302 (41.3) | 23 (29.5) | 8 (28.6) | 15 (30.6) |
| Intermediate-2 | 197 (24.1) | 2 (22.2) | 171 (23.4) | 24 (30.8) | 10 (35.7) | 14 (28.6) |
| High risk | 136 (16.6) | 0 | 117 (16.0) | 19 (24.4) | 8 (28.6) | 10 (20.4) |
All percentages are calculated from the total number of cases with available data. Data are presented as n (%), unless otherwise specified.
Q1, first quartile; Q3, third quartile.
In 2016, the registration of mutational status to the Swedish MPN register was changed with the addition CALR, MPL, and JAK2 exon12 mutations, and therefore, the data are presented in 2 separate time periods.